DOCSLIB.ORG

Progesterone Receptor NR3C3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progesterone Receptor NR3C3 Progesterone Receptor NR3C3 Progesterone receptor (PR) is a member of the steroid/thyroid hormone-retinoid receptor superfamily of ligand-activated nuclear transcription factors. Progesterone receptor plays a vital role in female reproductive tissue development, differentiation, and maintenance. Progesterone receptor is able to bind to a large number and variety of ligands that elicit a broad range of transcriptional responses ranging from full agonism to full antagonism and numerous mixed profiles inbetween. Progesterone receptor, such as progesterone, induces conformation changes in PR ligand binding domain (LBD), thus mediates subsequent gene regulation cascades. In humans, the biological response to progesterone is mediated by two distinct forms of the progesterone receptor (human PR-A and PR-B). www.MedChemExpress.com 1 Progesterone Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators 17α-Hydroxyprogesterone Altrenogest (17-Hydroxyprogesterone; 17-OHP) Cat. No.: HY-B0891 (Allyltrenbolone; RU2267) Cat. No.: HY-B0521 17α-Hydroxyprogesterone (17-Hydroxyprogesterone) Altrenogest (Allyltrenbolone) is a progestogen is an endogenous progestogen as well as chemical structurally related to veterinary steroid intermediate in the biosynthesis of other steroid trenbolone. hormones, including the corticosteroids and the androgens and the estrogens. Purity: 99.94% Purity: 99.80% Clinical Data: Launched Clinical Data: No Development Reported Size: 10 mM × 1 mL, 100 mg Size: 10 mM × 1 mL, 100 mg, 500 mg Asoprisnil Chlormadinone acetate (J867) Cat. No.: HY-119433 Cat. No.: HY-B1095 Asoprisnil (J867), a selective progesterone Chlormadinone acetate is a steroidal progestin, receptor modulator, exhibits mixed progesterone with antiandrogen and antiestrogenic effects. agonist and antagonist effects on various progesterone targeted tissues in animal and human. Purity: 98.30% Purity: ≥98.0% Clinical Data: Clinical Data: Launched Size: 1 mg Size: 10 mM × 1 mL, 100 mg Cridanimod Desogestrel Cat. No.: HY-W011890 (Org-2969) Cat. No.: HY-12516 Cridanimod is a potent progesterone receptor (PR) Desogestrel(Org-2969) is a third-generation activator mediated through induction of IFNα and 19-nortestosterone derivative progestogen; is IFNβ expression. Cridanimod is a small-molecule contained in many oral contraceptive preparations, immunomodulator and interferon inducer. both combined (COCs) to ethinyl-estradiol (EE) or alone in a progestin-only pill (POP). Purity: 99.97% Purity: 99.70% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Dienogest Drospirenone (STS 557) Cat. No.: HY-B0084 (Dihydrospirorenone) Cat. No.: HY-B0111 Dienogest(STS-557) is a specific progesterone Drospirenone(Dihydrospirorenone) is a synthetic receptor agonist with potent oral endometrial progestin that is an analog to spironolactone. activity and is used in the treatment of endometriosis. Target: progesterone receptor agonist Dienogest is an orally active synthetic progesterone (or progestin). Purity: 99.83% Purity: 98.45% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg Dydrogesterone Estradiol dipropionate Cat. No.: HY-B0257A Cat. No.: HY-B2245 Dydrogesterone is a potent, orally active Estradiol dipropionate is a combined progestogen indicated in a wide variety of estrogen-progesterone, acts as an estrogen and gynaecological conditions related to progesterone progesterone agonist. deficiency. Purity: 99.98% Purity: ≥98.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg 2 Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Ethynodiol diacetate Gestodene (Ethynodiol acetate) Cat. No.: HY-B1089 (SHB 331; WL 70) Cat. No.: HY-B0110 Ethynodiol diacetate (Ethynodiol acetate) is a Gestodene(SHB 331;WL 70) is a progestogen hormonal steroidal progestin which is used as a hormonal contraceptive. Target: Estrogen Receptor/ERR contraceptive, it has relatively little or no Gestodene is androgenically neutral, meaning that potency as an androgen,has significant estrogenic contraceptive pills containing gestodene do not effects. exhibit the androgenic side effects (e.g. Purity: 98.58% Purity: 99.69% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 500 mg Size: 10 mM × 1 mL, 50 mg, 100 mg Gestonorone Capronate Levonorgestrel (Gestonorone caproate) Cat. No.: HY-U00091 (D-Norgestrel) Cat. No.: HY-B0257 Gestonorone Capronate is a progestin for the Levonorgestrel is a synthetic progestogen used as treatment of benign prostatic hypertrophy and an active ingredient in some hormonal endometrial cancer. contraceptives. Purity: >98% Purity: 99.13% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 100 mg, 500 mg Medroxyprogesterone Medroxyprogesterone acetate (17α-Hydroxy-6α-methylprogesterone; U8840) Cat. No.: HY-B0648 (Medroxyprogesterone 17-acetate; Farlutin) Cat. No.: HY-B0469 Medroxyprogesterone is a progestin, a synthetic Medroxyprogesterone acetate is a widely used variant of the human hormone progesterone and a synthetic steroid by its interaction with potent progesterone receptor agonist. Target: progesterone, androgen and glucocorticoid Progesterone Receptor Medroxyprogesterone (MP), is receptors. a steroidal progestin drug which was never marketed for use in humans. Purity: 99.43% Purity: 99.82% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g Size: 10 mM × 1 mL, 100 mg, 500 mg Medroxyprogesterone acetate D3 Megestrol acetate (Medroxyprogesterone 17-acetate D3; Farlutin D3) Cat. No.: HY-B0469S Cat. No.: HY-13676 Medroxyprogesterone acetate D3 is deuterium Megestrol acetate is a synthetic and orally active labeled Medroxyprogesterone acetate. progesteronal agent. Megestrol acetate is Medroxyprogesterone acetate is a widely used effective as an appetite stimulant for wasting synthetic steroid by its interaction with syndromes such as cachexia. Megestrol acetate progesterone, androgen and glucocorticoid decreases nuclear and cytosol androgen receptors receptors. human BPH tissue. Purity: 98.06% Purity: 99.81% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mg Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g Mifepristone Nestoron (RU486; RU 38486) Cat. No.: HY-13683 (ST-1435; Elcometrine) Cat. No.: HY-13071 Mifepristone (RU486) is a progesterone receptor Nestoron (ST-1435) is a 19-norprogesterone (PR) and glucocorticoid receptor (GR) antagonist derivative with high affinity and selectivity for with IC50s of 0.2 nM and 2.6 nM in in vitro assay. progesterone receptors. Nestoron is a highly selective and potent progestogen that can be used as a hormonal contraceptive. Purity: 98.67% Purity: 99.41% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg Size: 10 mM × 1 mL, 10 mg, 50 mg www.MedChemExpress.com 3 Nomegestrol Nomegestrol acetate Cat. No.: HY-105634 Cat. No.: HY-105634A Nomegestrol is a potent and orally available Nomegestrol acetate is a potent, highly selective progestin, acts as a selective full progesterone progestogen, which is characterized as a full receptor agonist, with a Kd of 5.44 nM for rat agonist at the progesterone receptor, with no or uterine progesterone receptor, and has moderate minimal binding to other steroid receptors, antiandrogenic activity and strong antiestrogenic including the androgen and glucocorticoid activity. receptors. Purity: >98% Purity: 98.50% Clinical Data: Launched Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg Norethindrone Norethindrone acetate (Norethisterone) Cat. No.: HY-B0554 (19-Norethindrone acetate) Cat. No.: HY-B1710 Norethindrone is a female progestin approved by Norethindrone acetate is a female hormone used for FDA for the treatment of endometriosis, uterine the research of endometriosis. bleeding caused by abnormal hormone levels, and secondary amenorrhea. Purity: 99.57% Purity: 99.41% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 500 mg Size: 10 mM × 1 mL, 100 mg, 500 mg Norethisterone enanthate Norgestimate (Norigest) Cat. No.: HY-A0285 Cat. No.: HY-W013172 Norethisterone enanthate is a long-acting Norgestimate, a synthetic progesterone analog, is parenteral progestogen. Norethisterone enanthate an orally active progestin with highly selective is orally active. progestational activity and minimal androgenicity. Norgestimate is used for an oral contraceptive. Purity: 99.50% Purity: ≥99.0% Clinical Data: Launched Clinical Data: Launched Size: 10 mM × 1 mL, 100 mg, 250 mg, 500 mg Size: 10 mg PF-02413873 PF-3882845 (PF-2413873) Cat. No.: HY-11028 Cat. No.: HY-12738 PF-02413873 (PF-2413873) is a potent selective, PF-3882845 is a remarkably high affinity selective fully competitive and orally active nonsteroidal and orally efficacious mineralocorticoid progesterone receptor (PR) antagonist, with a Ki receptor (MR binding IC50=2.7 nM) antagonist of 2.6 nM. PF-02413873 can block progesterone for hypertension and nephropathy. PF-3882845 also binding and PR nuclear translocation, and inhibit binds to progesterone receptor (PR) with the endometrial growth in vivo. binding IC50 of 310 nM. Purity: ≥99.0% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg Size: 1 mg, 5
Load more

Recommended publications
  • Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds
    molecules Review Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds Danuta Wojcieszy ´nska , Ariel Marchlewicz and Urszula Guzik * Institute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Science, University of Silesia in Katowice, Jagiello´nska28, 40-032 Katowice, Poland; [email protected] (D.W.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +48-3220-095-67 Academic Editors: Urszula Guzik and Danuta Wojcieszy´nska Received: 10 September 2020; Accepted: 25 September 2020; Published: 29 September 2020 Abstract: The rising pollution of the environment with endocrine disrupting compounds has increased interest in searching for new, effective bioremediation methods. Particular attention is paid to the search for microorganisms with high degradation potential and the possibility of their use in the degradation of endocrine disrupting compounds. Increasingly, immobilized microorganisms or enzymes are used in biodegradation systems. This review presents the main sources of endocrine disrupting compounds and identifies the risks associated with their presence in the environment. The main pathways of degradation of these compounds by microorganisms are also presented. The last part is devoted to an overview of the immobilization methods used for the purposes of enabling the use of biocatalysts in environmental bioremediation. Keywords: EDCs; hormones; degradation; immobilization; microorganisms 1. Introduction The development of modern tools for the separation and identification of chemical substances has drawn attention to the so-called micropollution of the environment. Many of these contaminants belong to the emergent pollutants class. According to the Stockholm Convention they are characterized by high persistence, are transported over long distances in the environment through water, accumulate in the tissue of living organisms and can adversely affect them [1].
    [Show full text]
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • Abnormal Uterine Bleeding: Strategies for Management”
    PRE-CONGRESS COURSE 4 SIG Endometriosis & Endometrium “Abnormal uterine bleeding: strategies for management” CONTENTS Program overview p. 1 Speakers’ contributions • Abnormalities of menstrual bleeding: getting our terminologies right - I. Fraser (AUS) p. 3 • Abnormal uterine bleeding: the patient perspective - P. Warner (UK) p. 13 • Optimising strategies for evaluation and management of abnormal uterine bleeding - A. Prentice (UK) p. 32 • Unscheduled bleeding with exogenous hormone administration – P. Rogers (AUS) p. 33 • Strategies to control; endometrial bleeding - D. Archer (USA) p. 46 • Local mechanisms responsible for endometrial bleeding - H. Critchley (UK) p. 49 • Is there a role for selective progesterone receptor modulators in management of uterine bleeding? - K. Chwalisz (USA) p. 61 • Should menstruation be optional? – Health benefits of amenorrhoea – D. Baird (UK) p. 72 PRE-CONGRESS COURSE 4 - PROGRAMME SIG Endometriosis & Endometrium Abnormal uterine bleeding: strategies for management Course co-ordinators: H. Critchley (UK) & Th. D’Hooghe (B) Course description: Problematic uterine bleeding impairs quality of life for many women and often involves invasive treatments and significant cost. Agreement is needed on terminology and defi nitions in order to facilitate the establishment of multi-centre clinical trials evaluating the strategies for management. Contemporary management also requires an understanding of the patient’s perspective of her complaint and an understanding of acceptability to women of the available modes of investigation and treatment options. Optimal therapies will only be possible with a detailed understanding of the mechanisms involved in endometrial bleeding including unscheduled bleeding with exogenous hormone administration. Novel therapies need to be evaluated in the context of potential health benefits from therapies that reduce the number of menstrual cycles experienced by women.
    [Show full text]
  • Bipolar Androgen Therapy (BAT) in Men with Prostate Cancer
    Bipolar Androgen Therapy (BAT) in men with prostate cancer Samuel Denmeade, MD Professor of Oncology, Urology and Pharmacology The Johns Hopkins University School of Medicine, Baltimore, MD Presentation Overview • Androgen and Androgen Signaling 101 • Rationale For Bipolar Androgen Therapy (BAT) • Results from the RESTORE study testing BAT in Castration Resistant Prostate Cancer • The multi-center TRANSFORMER Trial • Future Directions • Results of BATMAN trial testing BAT as part of Intermittent Hormone Therapy strategy Testosterone Replacement Anabolic Steroids Trenbolone Acetate (Fina-Finaplix H pellets) High Dose Testosterone as Treatment for Prostate Cancer What Are Androgens? • Steroid hormone which can bind to Androgen Receptor – Testosterone, Dihydrotestosterone (DHT), DHEA, Androstenedione… • Sexual Differentiation – Needed to make a Male (Female is Default) • Primary Sex Characteristics: – Spermatogenesis – Accessory Sex Tissue Maintenance • Penis, Prostate... • Secondary Sex Characteristics: – Bone density – Muscle mass – Libido – Hair growth – Hematopoiesis What is a Steroid Hormone? Testosterone (T) Dihydrotestosterone (DHT) Estrogen How are Androgens Made? Androgen Receptor Signaling 101 Androgen Active Androgen Receptor (Testosterone) Androgen Receptor How Do Androgens Effect the Prostate Cell? NTD- Signaling Part DBD- DNA Binding Part LBD- Androgen Binding Part Cytoplasm Cell Nucleus Binds and activates genes: -Cell Growth -Cell Survival -Make prostate stuff like PSA, Acid Phosphatase, etc. DNA The Devilish Prostate • Physiologic
    [Show full text]
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Chapter 2 PET and SPECT Imaging of Steroid Hormone Receptors
    University of Groningen PET imaging of brain sex steroid hormone receptors and the role of estrogen in depression Khayum, Mohamed Abdul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Publication date: 2015 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Khayum, M. A. (2015). PET imaging of brain sex steroid hormone receptors and the role of estrogen in depression. University of Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 27-09-2021 Chapter 2 PET and SPECT Imaging of Steroid Hormone Receptors Khayum MA, Doorduin J, Glaudemans AWJM, Dierckx RAJO, de Vries EFJ. PET and SPECT of Neurobiological Systems, R.A.J.O. Dierckx et al. (eds.) DOI 10.1007/978-3-642-42014-6_14, © Springer-Verlag Berlin Heidelberg 2014 Chapter 2 Abstract Steroid hormones like estrogens, progestins, androgens and corticosteroids are involved in normal brain function.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
    Edinburgh Research Explorer Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women Citation for published version: Brache, V, Sitruk-Ware, R, Williams, A, Blithe, D, Croxatto, H, Kumar, N, Kumar, S, Tsong, Y-Y, Sivin, I, Nath, A, Sussman, H, Cochon, L, Miranda, MJ, Reyes, V, Faundes, A & Mishell, D 2012, 'Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women', Contraception, vol. 85, no. 5, pp. 480-8. https://doi.org/10.1016/j.contraception.2011.10.003 Digital Object Identifier (DOI): 10.1016/j.contraception.2011.10.003 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Contraception Publisher Rights Statement: NIH Public access author manuscript General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2013 May 01.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]